These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 28452904)

  • 1. A Placebo-Controlled Crossover Trial of Gastrin-Releasing Peptide in Childhood Autism.
    Marchezan J; Becker M; Schwartsmann G; Ohlweiler L; Roesler R; Renck LB; Gonçalves MMM; Ranzan J; Riesgo RDS
    Clin Neuropharmacol; 2017; 40(3):108-112. PubMed ID: 28452904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement in Symptoms of Autism Spectrum Disorder in Children With the Use of Gastrin-Releasing Peptide: An Open Trial.
    Becker MM; Riesgo RS; Roesler R; Bosa C; Ohlweiler L; Backes B; Endres RG; Zanon RB; Marchezan J; Schwartsmann G
    Clin Neuropharmacol; 2016; 39(5):215-9. PubMed ID: 27332629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. l-Carnosine As an Adjunctive Therapy to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Hajizadeh-Zaker R; Ghajar A; Mesgarpour B; Afarideh M; Mohammadi MR; Akhondzadeh S
    J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):74-81. PubMed ID: 29027815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risperidone Combination Therapy With Propentofylline for Treatment of Irritability in Autism Spectrum Disorders: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Behmanesh H; Moghaddam HS; Mohammadi MR; Akhondzadeh S
    Clin Neuropharmacol; 2019; 42(6):189-196. PubMed ID: 31725473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of autism spectrum disorder symptoms in three children by using gastrin-releasing peptide.
    Becker MM; Bosa C; Oliveira-Freitas VL; Goldim JR; Ohlweiler L; Roesler R; Schwartsmann G; Riesgo Rdos S
    J Pediatr (Rio J); 2016; 92(3):302-6. PubMed ID: 26893210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simvastatin as an Adjunctive Therapy to Risperidone in Treatment of Autism: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Moazen-Zadeh E; Shirzad F; Karkhaneh-Yousefi MA; Khezri R; Mohammadi MR; Akhondzadeh S
    J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):82-89. PubMed ID: 28719227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galantamine efficacy and tolerability as an augmentative therapy in autistic children: A randomized, double-blind, placebo-controlled trial.
    Ghaleiha A; Ghyasvand M; Mohammadi MR; Farokhnia M; Yadegari N; Tabrizi M; Hajiaghaee R; Yekehtaz H; Akhondzadeh S
    J Psychopharmacol; 2014 Jul; 28(7):677-85. PubMed ID: 24132248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder.
    Rezaei V; Mohammadi MR; Ghanizadeh A; Sahraian A; Tabrizi M; Rezazadeh SA; Akhondzadeh S
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Oct; 34(7):1269-72. PubMed ID: 20637249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prednisolone as Adjunctive Treatment to Risperidone in Children With Regressive Type of Autism Spectrum Disorder: A Randomized, Placebo-Controlled Trial.
    Malek M; Ashraf-Ganjouei A; Moradi K; Bagheri S; Mohammadi MR; Akhondzadeh S
    Clin Neuropharmacol; 2020; 43(2):39-45. PubMed ID: 32168067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-acetylcysteine as an adjunctive therapy to risperidone for treatment of irritability in autism: a randomized, double-blind, placebo-controlled clinical trial of efficacy and safety.
    Nikoo M; Radnia H; Farokhnia M; Mohammadi MR; Akhondzadeh S
    Clin Neuropharmacol; 2015; 38(1):11-7. PubMed ID: 25580916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using venlafaxine to treat behavioral disorders in patients with autism spectrum disorder.
    Carminati GG; Gerber F; Darbellay B; Kosel MM; Deriaz N; Chabert J; Fathi M; Bertschy G; Ferrero F; Carminati F
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Feb; 65():85-95. PubMed ID: 26361994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, effectiveness, and economic evaluation of an herbal medicine, Ukgansangajinpibanha granule, in children with autism spectrum disorder: a study protocol for a prospective, multicenter, randomized, double-blinded, placebo-controlled, parallel-group clinical trial.
    Lee SH; Shin S; Kim TH; Kim SM; Do TY; Park S; Lee B; Shin HJ; Lee J; Lee JY; Chang GT
    Trials; 2019 Jul; 20(1):434. PubMed ID: 31307524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study.
    Wasserman S; Iyengar R; Chaplin WF; Watner D; Waldoks SE; Anagnostou E; Soorya L; Hollander E
    Int Clin Psychopharmacol; 2006 Nov; 21(6):363-7. PubMed ID: 17012983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resveratrol as adjunctive therapy in treatment of irritability in children with autism: A double-blind and placebo-controlled randomized trial.
    Hendouei F; Sanjari Moghaddam H; Mohammadi MR; Taslimi N; Rezaei F; Akhondzadeh S
    J Clin Pharm Ther; 2020 Apr; 45(2):324-334. PubMed ID: 31714621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atomoxetine, Parent Training, and Their Combination in Children With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.
    Handen BL; Aman MG; Arnold LE; Hyman SL; Tumuluru RV; Lecavalier L; Corbett-Dick P; Pan X; Hollway JA; Buchan-Page KA; Silverman LB; Brown NV; Rice RR; Hellings J; Mruzek DW; McAuliffe-Bellin S; Hurt EA; Ryan MM; Levato L; Smith T
    J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):905-15. PubMed ID: 26506581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulforaphane as an adjunctive treatment for irritability in children with autism spectrum disorder: A randomized, double-blind, placebo-controlled clinical trial.
    Momtazmanesh S; Amirimoghaddam-Yazdi Z; Moghaddam HS; Mohammadi MR; Akhondzadeh S
    Psychiatry Clin Neurosci; 2020 Jul; 74(7):398-405. PubMed ID: 32347624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder.
    Umbricht D; Del Valle Rubido M; Hollander E; McCracken JT; Shic F; Scahill L; Noeldeke J; Boak L; Khwaja O; Squassante L; Grundschober C; Kletzl H; Fontoura P
    Neuropsychopharmacology; 2017 Aug; 42(9):1914-1923. PubMed ID: 27711048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, Placebo-Controlled Trial of Methyl B12 for Children with Autism.
    Hendren RL; James SJ; Widjaja F; Lawton B; Rosenblatt A; Bent S
    J Child Adolesc Psychopharmacol; 2016 Nov; 26(9):774-783. PubMed ID: 26889605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Retrospective Naturalistic Study of Ziprasidone for Irritability in Youth with Autism Spectrum Disorder.
    Dominick K; Wink LK; McDougle CJ; Erickson CA
    J Child Adolesc Psychopharmacol; 2015 Jun; 25(5):397-401. PubMed ID: 26091194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial.
    Stein MA; Sikirica V; Weiss MD; Robertson B; Lyne A; Newcorn JH
    CNS Drugs; 2015 Nov; 29(11):953-62. PubMed ID: 26547425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.